secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVS HEALTH Corp (CVS)
CIK:        0000064803
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0000064803-23-000046
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVS Health Q3 revenue $89.8B (+10.6%), GAAP EPS $1.75, Adj EPS $2.21, FY GAAP EPS guidance revised to $6.37-$6.61
--------------------------------------------------------------------------------

- Total revenues $89.8B, up 10.6% YoY; GAAP diluted EPS $1.75 vs loss of $2.59 prior year.
- Adjusted EPS $2.21 vs $2.17 prior year; YTD cash flow from operations $16.1B.
- FY GAAP EPS guidance revised to $6.37-$6.61 from $6.53-$6.75; adjusted EPS guidance confirmed at $8.50-$8.70.
- Launched Cordavis to commercialize biosimilars; Aetna's 2024 Medicare offerings expanded.
- Appointed Scott Kirby (United Airlines CEO) and Michael Mahoney (Boston Scientific CEO) to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/64803/000006480323000046/0000064803-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/64803/000006480323000046/cvs-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000064803-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer